喘舒片联合沙美特罗替卡松治疗支气管哮喘急性发作期的临床研究

目的 探讨喘舒片联合沙美特罗替卡松治疗支气管哮喘急性发作期的临床疗效。方法 选取2021年10月—2023年11月定州市人民医院收治的支气管哮喘症患者120例。依据用药情况分为对照组和治疗组，每组各60例。对照组患者吸入沙美特罗替卡松吸入气雾剂，1揿/次，2次/d。在对照组的基础上，治疗组口服喘舒片，2片/次，3次/d；两组用药7 d观察治疗情况。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，哮喘控制试验评分（ACT）和哮喘生活质量评分量表（AQLQ）评分，及血管内皮生长因子（VEGF）、血管细胞黏附分子（VCAM-1）、C反应蛋白（CRP）、呼气一氧化氮（FeNO）水平、用力肺活量（FVC）、第1秒用力呼气量（FEV1）和第1秒用力呼气容积占用力肺活量百分比（FEV1/FVC）指标水平。结果 治疗后，治疗组临床总有效率为96.67%，明显高于对照组（83.33%，P＜0.05）。治疗后，治疗组咳嗽、喘息、胸痛、气促等症状好转时间均明显早于对照组（P＜0.05）。治疗后，两组患者ACT评分、AQLQ评分比治疗前均明显升高（P＜0.05），且治疗组ACT评分、AQLQ评分均明显高于对照组（P＜0.05）。治疗后，两组患者VEGF、VCAM-1、CRP、FeNO水平比治疗前明显降低，而FVC、FEV1、FEV1/FVC水平明显升高（P＜0.05），且治疗组患者上述指标水平明显好于对照组（P＜0.05）。结论 喘舒片联合沙美特罗替卡松可极大改善哮喘急性发作期患者症状，减弱机体内炎性反应，显著提升生活质量。

Clinical study on Chuanshu Tablets combined with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol in treatment of bronchial asthma

Objective To explore the clinical effect of Chuanshu Tablets combined with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol in treatment of bronchial asthma. Methods Patients (120 cases) with bronchial asthma in Dingzhou People''s Hospital from October 2021 to November 2023were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were administered with Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol, 1 press/time, twice daily. Patients in the treatment group were po administered with Chuanshu Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores of ACT and AQLQ, and the levels of VEGF, VCAM-1, CRP, FeNO, FVC, FEV1 and FEV1/FVC in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.67%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the improvement time of cough, wheezing, chest pain and shortness of breath in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, ACT scores and AQLQ scores of the two groups were significantly higher than those before treatment (P < 0.05), and ACT scores and AQLQ scores of the treatment group were significantly higher than those of the control group (P < 0.05). After treatment, the levels of VEGF, VCAM-1, CRP and FeNO in two groups were significantly lower than those before treatment, while the levels of FVC, FEV1 and FEV1/FVC were significantly increased (P < 0.05), and the above-mentioned indexes in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Salmeterol fluticasone combined with Chuanshu Tablets can greatly improve the symptoms of patients with acute asthma, reduce the inflammatory response in the body, and significantly improve the quality of life.